Previous 10 | Next 10 |
2023-05-09 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q1 Non-GAAP EPS of $0.47 misses by $0.01 . Revenue of $162.14M (+38.2% Y/Y) misses by $13.38M . The 38% year-over-year increase was driven by an increase in royalty revenue primarily a...
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 38% YOY to $162.1 million ; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY t...
2023-04-26 15:10:00 ET Summary Equity markets started the year strong, with small cap stocks posting double digit gains through early February. The portfolio was virtually flat on a net basis (-0.06%), outpacing the R2000V’s decline of -0.7% but below the R2500V’s ri...
Halozyme To Report First Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating res...
2023-04-24 05:37:42 ET Genmab ( GMAB ) said it is filing a review of an award dismissing its claims in the second arbitration linked to a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Th...
2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...
2023-04-12 07:38:16 ET Summary Halozyme Therapeutics (HALO) is a biotech company with a unique platform technology, ENHANZE, that allows for the subcutaneous delivery of biologics. Recent CMS guidance related to Medicare drug price negotiations under the Inflation Reduction Act (I...
2023-03-28 06:24:51 ET Summary Shares have lost over half their value during the past year. Commercial momentum appears to be building with management guiding for break-even cash flow by the end of 2023. Keveyis is facing generic competition in PPP and Recorlev is still in the...
2023-03-15 09:32:54 ET Halozyme Therapeutics ( NASDAQ: HALO ) said the Opposition Division of the European Patent Office revoked a Janssen's European Patent related to cancer Darzalex, but the company noted that it expects no impact on its royalty revenue from the drug. ...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO ® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 mill...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...